Bayerische Motoren Werke ADR (BMWYY)
29.20
+0.00 (0.00%)
OP · Last Trade: Aug 11th, 1:17 PM EDT
Detailed Quote
| Previous Close | 29.20 |
|---|---|
| Open | - |
| Bid | - |
| Ask | - |
| Day's Range | N/A - N/A |
| 52 Week Range | 25.15 - 31.77 |
| Volume | 0 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | - |
Chart
News & Press Releases
The Federal Reserve finds itself in a precarious position, navigating a complex economic landscape heavily influenced by the unpredictable nature of President Trump's tariff policy. As of August 2025, the central bank maintains a cautious "wait-and-see" approach to its benchmark interest rate, holding it steady at a target range of
Via MarketMinute · August 8, 2025
Breakthrough Treatment for Lung Cancer Uses Mitochondria to Supercharge Immune Cells
Researchers in China have discovered a way to supercharge the treatment of lung cancer by transplanting mitochondria into the tumor environment. This transplantation increases the effectiveness of chemotherapy while boosting the immune system’s ability to fight the cancer. The team combined cisplatin (a lung cancer chemo drug) with mitochondrial transplantation.
Via Investor Brand Network · August 8, 2025
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Secures FDA Type C Meeting for AVERSA(TM) Fentanyl Abuse-Deterrent Patch
Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, announced the U.S. Food and Drug Administration has granted a Type C Meeting on Sept. 18, 2025, to review Chemistry, Manufacturing, and Controls plans for its lead product, AVERSA(TM) Fentanyl. Developed in partnership with Kindeva, the patch integrates Nutriband’s abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch to help prevent abuse, diversion, misuse, and accidental exposure while maintaining access for patients in need. Positioned to be the world’s first abuse-deterrent opioid patch, AVERSA Fentanyl targets peak annual U.S. sales potential of $80 million to $200 million, with future global market expansion planned. The technology is protected by patents in 46 countries.
Via Investor Brand Network · August 8, 2025
How to Rebuild Trust in the US Healthcare System
A recent survey undertaken by Gallup in 2025 found that since 2021, there has been a 14% drop in the level of the public’s trust in the physicians who take care of them. This decline was the steepest among the declines registered by all the professions focused on.
Via Investor Brand Network · August 7, 2025
Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF): The Cancer Detection Revolution That Could Make Breast Cancer Deaths Preventable
The medical community stands at the threshold of what could become the most significant advancement in cancer detection since the introduction of mammography over half a century ago. While survival rates for many cancers have improved dramatically through better treatments, the fundamental challenge of early detection remains largely unchanged. Current screening technologies, despite decades of refinement, still miss cancers in their earliest, most treatable stages, while simultaneously generating false positives that lead to unnecessary anxiety and interventions.
Via Investor Brand Network · August 8, 2025
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Secures Full Patent Coverage for New Crystalline Form of Buntanetap
Annovis Bio (NYSE: ANVS), a late-stage clinical company advancing treatments for neurodegenerative diseases, announced the successful transfer and expansion of its intellectual property to fully cover both the original and new crystalline forms of buntanetap. The comprehensive patent portfolio, now protected through 2046, includes composition of matter, mechanism of action, and use in multiple indications. The new form offers improved stability with bioequivalence confirmed in animal and human studies, as presented at the 2025 Alzheimer’s Association International Conference.
Via Investor Brand Network · August 7, 2025
BioMedNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Launches Multilingual Podcast to Raise Awareness of Breast Imaging Innovation
Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company advancing imaging technologies for breast cancer detection, has launched a multilingual podcast series titled Beyond the Mammogram: Rethinking the Future of Breast Imaging . Available in seven languages, the series aims to inform global audiences about limitations in current imaging tools and the need for more accurate technologies like Izotropic’s IzoView Breast CT system. The podcast repurposes public data into educational content for patients, professionals, and stakeholders as the Company moves toward regulatory approval.
Via Investor Brand Network · August 7, 2025
Lantern Pharma Inc. (NASDAQ: LTRN) Completes Japanese Enrollment for LP-300 Phase 2 HARMONIC(TM) Trial Ahead of Schedule
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development, has completed targeted patient enrollment in Japan for its ongoing Phase 2 HARMONIC(TM) clinical trial evaluating investigational drug candidate LP-300 in never-smoker non-small cell lung cancer (“NSCLC”) patients ( https://ibn.fm/JXFqG ).
Via Investor Brand Network · August 7, 2025
Solid Power (SLDP) Q2 2025 earnings beat estimates with $7.5M revenue, narrower EPS loss. BMW and SK On partnerships advance solid-state battery tech. Shares rise cautiously.
Via Chartmill · August 6, 2025
HeartBeam Inc. (NASDAQ: BEAT) FDA-Cleared System Provides Momentum as Company Moves to Innovate Cardiac Care
Foundational clearance from the U.S. Food and Drug Administration (“FDA”) for its patented HeartBeam system has proved pivotal for HeartBeam (NASDAQ: BEAT), a cardiac technology company focused on transforming the cardiac-care space ( https://ibn.fm/0TAG4 ). The first cable-free, high-fidelity ECG device that captures the heart’s electrical activity from three distinct directions, the HeartBeam system enables patients and physicians to access critical arrhythmia data outside traditional clinical settings.
Via Investor Brand Network · August 6, 2025
Nutriband Inc. (NASDAQ: NTRB) Navigates Drug-Delivery Challenges with Innovation in Abuse-Deterrent Tech
Developing safe, effective and abuse-deterrent delivery systems for controlled substances such as fentanyl is a formidable challenge, and Nutriband (NASDAQ: NTRB) is positioning itself at the forefront of that effort. The company is pioneering transdermal technologies to deliver medications that require careful balancing of patient access with strong mitigation against misuse.
Via Investor Brand Network · August 6, 2025
Humanoid robots, once confined to the realm of science fiction, are rapidly transitioning into tangible products available for purchase. While the market is still in its nascent stages, these advanced machines are finding diverse applications, ranging from industrial automation and cutting-edge research to educational tools and even emerging consumer-grade personal
Via MarketMinute · August 6, 2025
Dallas, TX - August 6, 2025 - Dallas has a new destination for European auto enthusiasts who demand more from their repair, detailing, and performance experience. GB Motors, located at 11444 N Stemmons Fwy, is now open and raising the bar for European car care across the Dallas–Fort Worth metroplex.
Via Get News · August 6, 2025
HeartBeam Inc.’s (NASDAQ: BEAT) Two New U.S. Patents Power Next Generation of Cardiac Diagnostics
HeartBeam (NASDAQ: BEAT), a cardiac technology company, has secured two new U.S. patents that significantly enhance its intellectual property portfolio and strengthen its position in cardiac monitoring technology ( https://ibn.fm/6xni4 ). The company, focused on delivering powerful, personalized insights into heart health through its innovative 3D ECG platform, now holds more than 20 U.S. and international patents, with additional applications pending.
Via Investor Brand Network · August 5, 2025
Study Finds That Inflammation Markers in Diabetics Influence Depression Treatment Outcomes
On average, diabetics tend to suffer from depression at higher rates than is seen in the general population. A new study conducted by a team at the German Diabetes Center and other institutions in Germany has found that the markers of chronic inflammation influence how successful the treatments provided for depression will be for patients living with diabetes.
Via Investor Brand Network · August 5, 2025
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) to Present at Canaccord 45th Annual Growth Conference
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company developing treatments for neurodegenerative diseases such as ALS and MS, announced that its management will present at the Canaccord 45th Annual Growth Conference and participate in one-on-one investor meetings.
Via Investor Brand Network · August 5, 2025
BioMedNewsBreaks — Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Highlights Market Demand for Breast CT Imaging Innovation
Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) emphasized the global trends driving demand for advanced breast cancer imaging technologies and the advantages of its IzoView Breast CT Imaging System. With over 2.3 million new cases of breast cancer diagnosed worldwide annually and U.S. incidence projected to exceed 315,000 in 2025, healthcare systems face growing pressure to improve screening outcomes. Market forecasts show global breast imaging revenues rising from $5.4 billion in 2024 to $8.69 billion by 2030. IzoView addresses clinical and patient needs with non-compressive 3D imaging, offering a more comfortable, accurate, and scalable alternative to conventional modalities—especially for the 50% of women with dense breast tissue.
Via Investor Brand Network · August 5, 2025
Nutriband Inc. (NASDAQ: NTRB) Aligns Shareholder Value with FDA Milestone
Obtaining approval from the U.S. Food and Drug Administration (“FDA”) is a monumental achievement for any biopharmaceutical company, serving as a critical validation of a drug’s safety and efficacy. This rigorous process is a cornerstone of public health, ensuring that only treatments proven to be beneficial and with acceptable risks reach patients. Recognizing the immense value this milestone represents, Nutriband (NASDAQ: NTRB) recently underscored its commitment to this pathway by announcing a 25% preferred stock dividend as the company targets filing for FDA approval for its lead product, AVERSA(TM) Fentanyl ( https://ibn.fm/8FRUA ).
Via Investor Brand Network · August 5, 2025
Mordor Intelligence has published a new report on the Luxury EV Market offering a comprehensive analysis of trends, growth drivers, and future projections
Via Press Release Distribution Service · August 5, 2025
The global automotive industry is currently navigating a period of profound transformation, marked by groundbreaking strategic shifts, evolving market dynamics, and significant leadership changes. Recent developments, including a colossal new pay package for Tesla (NASDAQ: TSLA) CEO Elon Musk tied to the company's ambitious robotaxi and humanoid robot ventures, the
Via MarketMinute · August 4, 2025
Irvine, Calif. – Modern Elite Transportation, a trusted name in executive ground travel since 2010, has launched a redesigned website that reflects its growing role as a mobility partner to professionals, event organizers, and institutions requiring precision and discretion. With operations centered in Southern California and now expanding globally, the company continues to embody its mission: Moving Those Who Move the World .
Via GetFeatured · August 4, 2025
Study Identifies Genetic Marker Helpful in Guiding Brain Tumor Treatment
Researchers at the University of Kentucky have identified a key genetic biomarker that treatment teams could rely on to predict which patients having glioblastoma stand higher chances of benefiting from bevacizumab, a cancer drug.
Via Investor Brand Network · August 1, 2025
BMW Group commenced its San Luis Potosí plant expansion in Mexico, with Jilian Group serving as the lead electromechanical engineering contractor. The expansion project in Mexico recently held its groundbreaking ceremony. Senior executives from Jilian joined BMW Mexico’s management team in witnessing this strategic milestone.
Via Binary News Network · August 1, 2025
New AI-Based Speech Tool Detects Possibility of Parkinson’s Disease
Computer scientists have designed an AI-based speech screening tool that could help people ascertain whether they could be exhibiting signs of Parkinson’s . The research explaining this speech tool appeared in the npj Parkinson’s Disease journal.
Via Investor Brand Network · July 31, 2025
